Abstract: The present invention is based, in part, on the discovery of the human-specific regulatory control of cGAS and the structure of the active human cGAS-DNA complex, as well as compositions comprising the modified hcGAS polypeptide, hcGAS-DNA complex, hcGAS-DNA-ATP complex, and methods of screening for modulators of the structure, expression, and/or activity of such polypeptides and complexes.

Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.

Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.

Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.

Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.

Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.

Abstract: New therapeutic methods and compositions are provided for treating against an infectious agent in a mammal by administration of a polymeric material having linked thereto a plurality of therapeutic agents against the infective agent, wherein the polymer comprises polymerized dextran or ethylene glycol units. The compositions and methods of the invention are particularly useful to treat against bacterial infections, including treatment of mammalian cells infected with gram-negative bacteria or gram-positive bacteria. The compositions of the invention can be useful for treating against anthrax, staphylococcus, pneumococcus and other bacteria, parasites, fungi, viral and protozoan infections.

Abstract: A live non-virulent vaccine composition and method for preparing the same comprising a virulent microorganismal strain which contains at least two mutations, wherein the first mutation results in an auxotrophic mutant which requires for proliferation, a nutrient which is normally available in the host tissues in an amount required by the auxotrophic mutant for proliferation and the second mutation results in the inability of the auxotrophic mutant to specifically transport the required nutrient from host-tissues into the auxotrophic mutant thereby producing an attenuated strain.

Abstract: The invention features a general system for the identification of essential genes in organisms. This system is applicable to the discovery of novel target genes for antimicrobial compounds, as well as to the discovery of genes that enhance cell growth or viability.

Abstract: V. cholerae vaccine strains which have a soft agar penetration-defective phenotype and methods for making such strains are described. Also described are methods for identifying new genes involved in V. cholerae motility and the cloning, identification, and sequencing of V. cholerae motB and fliC genes.

Abstract: A vector capable of integrating into the chromosome of Salmonella including a first DNA sequence encoding a heterologous protein, a second DNA sequence encoding a marker, and a third DNA sequence encoding a phoP regulatory region regulated gene product necessary for virulence, the third DNA sequence being mutationally inactivated.

Abstract: The invention provides bacterial strains with increased sensitivity to antibiotics and methods for making and using the strains.

Abstract: The invention features a nontoxigenic genetically stable mutant strain of V. cholerae which lacks any functional attRS1 sequences is useful as a live, oral vaccine for inducing immunological protection against cholera and a method for making same. The invention also features a killed, oral cholera vaccine comprising at least a first and a second V. cholerae strain, wherein at least one of the strains is a different serotype, and the vaccine also contains cholera toxin B subunit, produced by at least one of the serotypes.

Abstract: The invention features a Salmonella cell the virulence of which is attenuated by a deletion of a portion of the PhoQ gene and Salmonella cells having a deletion of the PhoQ gene and a deletion of the PhoP gene. The invention also features vaccines comprising such bacteria.

Abstract: A bacterial cell (preferably a gram-negative, enteric bacterium such as V. cholerae) the chromosome of which which contains a DNA sequence encoding a heterologous antigen, which sequence is functionally linked to an iron-regulated promoter such as the irgA promoter of V. cholerae.

Abstract: A vector capable of integrating into the chromosome of Salmonella including a first DNA sequence encoding a heterologous protein, a second DNA sequence encoding a marker, and a third DNA sequence encoding a phoP regulatory region regulated gene product necessary for virulence, the third DNA sequence being mutationally inactivated

Abstract: A bacterial cell the virulence of which is attentuated by a first mutation in a PhoP regulon and a second mutation in an aromatic amino acid synthetic gene and bacterial cells the virulence of which is attenuated by a mutation in one or more PhoP-activated genes or one or more PhoP-repressed genes.

Abstract: A vector capable of integrating into the chromosome of Salmonella including a first DNA sequence encoding a heterologous protein, a second DNA sequence encoding a marker, and a third DNA sequence encoding a phoP regulatory region regulated gene product necessary for virulence, the third DNA sequence being mutationally inactivated

Abstract: A vector capable of integrating into the chromosome of Salmonella including a first DNA sequence encoding a heterologous protein, a second DNA sequence encoding a marker, and a third DNA sequence encoding a phoP regulatory region regulated gene product necessary for virulence, the third DNA sequence being mutationally inactivated.

Abstract: The invention features a nontoxigenic genetically stable mutant strain of V. cholerae which lacks any functional attRS1 sequences is useful as a live, oral vaccine for inducing immunological protection against cholera and a method for making same. The invention also features a killed, oral cholera vaccine comprising at least a first and a second V. cholerae strain, wherein at least one of the strains is a different serotype, and the vaccine also contains cholera toxin B subunit, produced by at least one of the serotypes.